Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | MMP1 | P03956 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.57 |
| ▸ | MMP8 | P22894 | 2/20 | 0.57 |
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | DHFR | P00374 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153130 | 0.91 | CA1 (0.67) | KMT2AKEAP1LMNACA1CA2 | |
| SCHEMBL798074 | 0.86 | CA1 (0.64) | KMT2AKEAP1LMNAMEN1CA1 | |
| SCHEMBL29653769 | 0.86 | CA1 (0.64) | KMT2AKEAP1LMNAMEN1CA1 | |
| SCHEMBL31120812 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| Potassium SCHEMBL29568431 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| SCHEMBL6822933 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| SCHEMBL1302465 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| SCHEMBL29011157 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| Fluoride SCHEMBL28175459 | 0.84 | CA1 (0.61) | KMT2AKEAP1LMNAMEN1CA1 | |
| Aniline SCHEMBL11344792 | 0.83 | KEAP1 (0.56) | KMT2AKEAP1LMNAMEN1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| US-5817709-A | CURING AGENTS; CROSSLINKING | CYTEC TECHNOLOGY CORP. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5648434-A | AMINOPLAST CROSSLINKING AGENTS AND CATALYSTS | CYTEC TECHNOLOGY CORP. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643682-A | AMINOPLAST CROSSLINKING AGENTS AND CATALYSTS | CYTEC TECHNOLOGY CORP. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0453730-B1 | Sulfonimide catalysts for coatings | CYTEC TECH CORP (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0509138-B1 | Sulfonimide catalysts for coatings | CYTEC TECH CORP (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5256493-A | Crosslinking agent for heat curable coatings | CYTEC TECHNOLOGY CORP. | 1993-10-26 | — | — | US | disclosed |
| EP-0509138-A2 | Sulfonimide catalysts for coatings | CYTEC TECHNOLOGY CORP. (US) | 1992-10-21 | — | — | EP | disclosed |
| EP-0453730-A1 | Sulfonimide catalysts for coatings | CYTEC TECHNOLOGY CORP. (US) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | AMPD1, AMPD2, AMPD3 | KMT2A 1451/4885KEAP1 377/4885LMNA 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.